ANIXAnixa Biosciences Inc
ANIX
Anixa Biosciences Inc10,474
Mkt Cap
$94.55MVolume
110,361.0052W High
$5.4652W Low
$2.44PE Ratio
-8.95ANIX Fundamentals
Price
$2.82Prev Close
$2.89Open
$2.8450D MA
$2.85Beta
1.19Avg. Volume
116,525.38EPS (Annual)
-$0.3367P/B
6.26Rev/Employee
$0.00$117.85
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy PR Newswire SAN JOSE, Calif., May...
PR Newswire·6d ago
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV PR...
PR Newswire·16d ago
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology PR...
PR Newswire·18d ago
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting Anixa Biosciences Announces Presentation of its...
PR Newswire·25d ago
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference
Anixa Biosciences (NASDAQ:ANIX) CEO Dr. Amit Kumar outlined the company's strategy for advancing two clinical-stage oncology programs while maintaining what he described as a "very modest" cash burn during a Water Tower Research conference session moderated by Robert Sassoon, Managing Director of He...
MarketBeat·1mo ago
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 Anixa Biosciences to Participate in RedChip's Biotech...
PR Newswire·1mo ago
Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday...
MarketBeat·1mo ago
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 PR...
PR Newswire·1mo ago
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting...
PR Newswire·1mo ago
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered Anixa Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·1mo ago
<
1
2
...
>